Recent News

• 03.04.2025 - Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
• 03.04.2025 - Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
• 03.04.2025 - Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
• 02.28.2025 - Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
• 02.27.2025 - Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
• 02.19.2025 - Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
• 02.18.2025 - Daxor to Exhibit at World’s Largest Critical Care Conference
• 02.14.2025 - Daxor’s Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
• 02.13.2025 - New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care

Recent Filings

• 01.22.2025 - NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2024 - NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
• 09.10.2024 - N-PX Annual Report of proxy voting record of management investment companies
• 08.29.2024 - NPORT-P Monthly Portfolio Investments Report on Form N-PORT (Public)
• 08.29.2024 - N-CSRS Certified Shareholder Report, Semi-Annual
• 08.23.2024 - 40-17G Fidelity Bond [Rule 17G-1(g)]
• 08.16.2024 - N-2 Registration statement for closed-end investment companies